This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London.

Here, Dr Simon Stott talks about the sub-study being funded by Cure Parkinson’s which will investigate the effectiveness of nortriptyline in slowing the progression of Parkinson’s.

ADEPT-PD

Antidepressants Trial in Parkinson’s Disease (ADepT-PD): A randomised placebo-controlled trial on the effectiveness of the two drugs, nortriptyline and escitalopram, on low mood and depressive symptoms in Parkinson’s disease. Cure Parkinson’s is funding a sub-study of nortriptyline.

This trial will be run as an adjunct to the main trial, in which existing participants will simply undergo some additional assessments of their movement symptoms after a year of treatment with nortriptyline. This approach makes the most of participants’ time and efforts, and maximises all potential outcomes from a large scale study on symptom management, through additionally investigating the critical question on the potential of nortriptyline to alter the course of Parkinson’s. An exciting and novel feature of this approach will involve the use of wearable technology to allow continuous measurement of movement over a week, in addition to the standard ‘OFF-state’ assessments.

In this film, Dr Schrag talks about the ADepT-PD trial.

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?